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Prostate cancer generally metastasizes to bone, and most patients have tumor cells in their bone marrow already
at diagnosis. Tumor cells at the metastatic site may therefore progress in parallel with those in the primary tumor.
Androgen deprivation therapy is often the first-line treatment for clinically detectable prostate cancer bone
metastases. Although the treatment is effective, most metastases progress to a castration-resistant and lethal
state. To examine metastatic progression in the bone microenvironment, we implanted androgen-sensitive,
androgen receptor–positive, and relatively slow-growing Dunning G (G) rat prostate tumor cells into the tibial bone
marrow of fully immune-competent Copenhagen rats. We show that tumor establishment in the bone marrow was
reduced compared with the prostate, and whereas androgen deprivation did not affect tumor establishment or
growth in the bone, this was markedly reduced in the prostate. Moreover, we found that, with time, G tumor cells
in the bone microenvironment progress to a more aggressive phenotype with increased growth rate, reduced
androgen sensitivity, and increased metastatic capacity. Tumor cells in the bone marrow encounter lower
androgen levels and a higher degree of hypoxia than at the primary site, which may cause high selective pressures
and eventually contribute to the development of a new and highly aggressive tumor cell phenotype. It is therefore
important to specifically study progression in bone metastases. This tumor model could be used to increase our
understanding of how tumor cells adapt in the bone microenvironment and may subsequently improve therapy
strategies for prostate metastases in bone.
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Metastasis to bone is one of the most important clinical features of
prostate cancer (PC). Approximately 70%of patients have prostate tumor
cells in their bonemarrow already at diagnosis [1]. Although the existence
of such disseminated tumor cells (DTCs) is a predictor of recurrence
[1,2], not all of the DTCs grow into clinically detectable metastases [1].
Why only subsets of asymptomatic and dormant micrometastases
progress into clinical overt metastases is largely unknown.
Androgen deprivation therapy is a common first-line therapy for
metastatic PC. Although the initial response to androgen deprivation
is of significant palliative value, the metastases progress into an
incurable and fatal state termed castration-resistant PC. A better
understanding of the biology behind metastatic progression, from
dormant asymptomatic micrometastases to clinically detectable
metastases and from overt metastases to castration-resistant disease,
is therefore a key to development of more effective treatments for
metastatic PC.The ability to grow as a clinically detectable metastasis could be
acquired in the primary tumor [3–5]. It is also possible that neoplastic
cells that are able to survive in the bone microenvironment progress at
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regarding both intrinsic properties of the neoplastic cells and
development of a metastasis stroma [3–5]. The prognosis may
therefore depend on the ability of the initially dormant metastatic
cells to grow and interact with the different microenvironment at the
metastatic site.
PC cells have been shown to home to the hematopoietic stem cell
niche in bone and replace the hematopoietic stem cells, and this niche
appears to support tumor dormancy [6]. The formation of both
osteolytic and osteoblastic lesions at the metastatic site in bone suggests
that interactions with the microenvironment are crucial for the
establishment of bone metastases [7]. Moreover, both adaptive and
innate immunity may control the establishment of metastases. Low
levels of the histocompatibility leukocyte antigen class I molecule on
breast cancer cells have been suggested to be a way for DTCs to escape
from T-cell–induced cytotoxicity and subsequently facilitate metastatic
outgrowth [8]. The activity of T-cells may also be suppressed in the
bone microenvironment in PC [9]. Better in vivo models that enable
studies of metastatic progression in the factual microenvironment of
fully immune-competent animals are therefore needed. Furthermore,
bone marrow DTCs from breast, prostate, and esophageal cancer have
been shown to display significantly fewer genetic aberrations than
primary tumor cells [10–13], suggesting that they are disseminated early
during primary tumor progression. Cell lines from more advanced
metastatic tumors may therefore not be useful in studies of metastatic
progression, as the mechanisms that are crucial for early colonization
and adaptive selection may have been altered. Furthermore, neoplastic
cells continue to evolve genetically at the bone metastatic site, and
metastasis-to-prostate and metastasis-to-metastasis spread has been
shown to be common in PC patients [14,15].
Here we implanted androgen-sensitive, androgen receptor (AR)–
positive, and relatively slow-growing and poorly metastatic Dunning
G (G) rat prostate tumor cells [16] into the tibial bone marrow of
fully immune-competent Copenhagen rats. The aim of this study was
to develop an in vivo model that reflects several aspects of human PC
bone metastases and to determine whether the bone microenviron-
ment can induce stable changes in prostate tumor cells, primarily
regarding growth rate, the ability to colonize secondary organs, and
response to androgen deprivation.
Materials and Methods
Cell Culture and Animals
Androgen-sensitive, AR-positive, low-metastatic rat prostate G
R3327 tumor cells were grown in RPMI 1640 + GlutaMAX (Gibco)
supplemented with 10% fetal bovine serum (FBS) and 250 nM
dexamethasone [16]. Adult syngenic and fully immune-competent
male Copenhagen rats (Charles River, bred in our laboratory) were
used in all animal experiments. All the animal work was carried out in
accordance with protocols approved by the Umeå Ethical Committee
for Animal Studies (permit number A110-12).
Intraprostatic and Intratibial Implantation of G Prostate
Tumor Cells
For intraprostatic implantation simulating primary tumor growth,
the animals were anesthetized, and an incision was made in the lower
abdomen to expose the ventral prostate lobes. G tumor cells were
carefully injected into one of the ventral prostate lobes using a
Hamilton syringe. For intratibial injections simulating metastaticgrowth, the animals were anesthetized, and the right leg of the rat was
flexed. Using a drilling motion, a 23G needle was inserted via the
knee joint into the bone marrow cavity of the tibia, and G tumor cells
were then injected directly into the bone marrow cavity.
The same number of G tumor cells (2 × 105 cells in 10 μl of
RPMI) was implanted into the prostate or bone marrow as described
above, and the animals were sacrificed 8 weeks later (n = 10 rats with
prostate tumors, n = 10 rats with bone tumors) and 12 weeks later
(n = 6 rats with prostate tumors, n = 6 rats with bone tumors). The
prostatic tumors were removed and fixed in formalin for 24 hours,
dehydrated, and paraffin embedded. The right leg was cut above the
knee and formalin fixed for 48 hours, decalcified in formic acid–
sodium citrate solution (30% and 15%, respectively) for 48 hours,
dehydrated, and embedded in paraffin.
Castration Treatment
Rats were castrated by scrotal incision or they were sham operated
(control) 7 days before implantation of tumor cells.G tumor cells (2 × 106)
were implanted into the ventral prostate of castrated rats (n = 9) or control
rats (n = 8). In separate animals, G tumor cells were implanted into the
bone marrow of both tibias (2 × 106/tibia) in castrated rats (n = 5) and
control rats (n = 6) as described above. All animals were sacrificed 6 weeks
after implantation of tumor cells, and 1 hour before sacrifice, the animals
were injectedwith bromodeoxyuridine (BrdU, 50 mg/kg; Sigma-Aldrich),
and the tumors were removed and formalin fixed as described above.
In addition, G tumor cells were implanted into the ventral prostate
(2 × 103 cells) and the tibial bone marrow (2 × 105 cells) of the same
animals. After 8 weeks, the animals were randomized to receive sham
(n = 7) or castration treatment (n = 8). The animals were injected
with BrdU as described above and sacrificed 14 days after the
treatment was started.
To label hypoxic cells, additional animals that had been castrated
(n = 6) or sham operated (n = 5) for 7 days were injected with
Hypoxyprobe (Millipore) 1 hour before sacrifice, and the prostates,
livers, kidneys, and tibial bones were formalin fixed and embedded in
paraffin as described earlier [17]. Tissue oxygen was also measured
directly in the bone marrow and prostate in anesthetized rats using
electrodes (LIcox, Mediplast, Malmö, Sweden, probe CC1.2)
inserted in the same way as for intratibial or intraprostatic tumor
cell injection.
To measure dihydrotestosterone (DHT) and testosterone (T),
animals that had been castrated (n = 7) or sham operated (n = 7) for
7 days were sacrificed, and the ventral prostate lobes and the tibias
and femurs were immediately frozen in liquid nitrogen. In addition,
EDTA plasma was collected. DHT and T were measured in bone
marrow, prostate tissue, and plasma (at the Swedish Metabolomics
Centre, Umeå, Sweden) using liquid chromatography–tandem mass
spectrometry as previously described [18].
Morphological Analysis
Tumor area was assessed in hematoxylin and eosin–stained sections
using Pannoramic viewer software version 1.15 (3DHistech, www.
3dhistech.com). For G tumors in the prostate, the largest tumor area
of each tumor represented tumor size. In bone, the G tumors usually
grew as multiple tumors within the bone marrow cavity and
sometimes also in the joint cavity. Representative bone sections
were analyzed, and the section with the largest total tumor area (the
sum of all G tumor areas present) in each animal was chosen to
represent tumor size in bone. Sections were immunostained using
154 Prostate tumor progression in bone Bergström et al. Neoplasia Vol. 18, No. 3, 2016primary antibodies against BrdU (Dako), caspase-3 (Cell Signaling
Technology), and Hypoxyprobe (Chemicon) as previously described
[17]. To determine proliferation (BrdU) and apoptosis (caspase-3),
the fractions (i.e., percentages) of stained cells were assessed in
approximately 1000 cells.
Reestablishment of G Tumor Cells In Vitro
Rats were castrated or sham operated 7 days before intratibial
implantation of 2 × 105 G tumor cells. After 8 and 12 weeks, the
tumors were reestablished as tumor cell lines in vitro as previously
described [16]. Briefly, bone marrow containing the tumor cells was
excised aseptically, minced with scissors, and mixed with 10 ml of
0.1% collagenase in Hanks’ balanced salt solution (HBSS) containing
calcium and magnesium (Gibco) and incubated in 37°C for 1 hour.
The mixture was filtered through a 100-μm cell strainer (BD Falcon).
The first filtrate was discarded, the residue was washed on the cell
strainer with calcium- and magnesium-free HBSS (Gibco), and the
wash was discarded. The cells were gently pressed through the strainer
and washed with 20 ml of HBSS. The cells that passed through the
filter were centrifuged (500g for 5 min) and resuspended in complete
medium. Cells from each tumor group were pooled as one cell line
(n = 5 to 6 tumors/cell line) and incubated at 37°C, 5% CO2.
Western Blot
Protein was extracted from the reestablished G tumor cell lines as
previously described [19]. Equal amounts of total cell lysates were
separated on a 10% TGX gel under reduced conditions (Bio-Rad,
Sundbyberg, Sweden), blotted onto a nitrocellulose membrane using the
Trans-Blot Turbo transfer system (Bio-Rad), and incubated overnight at
4°C with an anti-AR antibody (PG-21; Upstate) and an anti–β-actin
antibody (A2066; Sigma-Aldrich). Following incubation with primary
antibodies and washing, the membranes were incubated with species-
appropriate IRDye secondary antibodies (800CW and 680RD; LI-COR
Biosciences, Cambridge, UK) for 1 hour at room temperature. The
membranes were analyzed using theOdyssey CLx system (LI-COR), and
relevant signal intensity was determined using LI-COR imaging software.
3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium Bromide
(MTT) Viability Assay
Viability was determined with the MTT assay (Roche Diagnos-
tics). Briefly, G tumor cells from bone (5 × 103 cells/well, 6 wells/cell
line and time point) were seeded in 100 μl of complete medium in
96-well plates and incubated in 37°C for 1 to 7 days. After each time
point, 10 μl of MTT labeling agent was added to each well and
incubated for an additionally 4 hours. Then, 100 μl of solubilization
solution was added to each well, with incubation overnight. The
absorbance was measured at 550 nm the following day and subtracted
with the reference wavelength at 650 nm.
For DHT and T stimulation, tumor cells were seeded in phenol red–
free (androgen-free) RPMI 1640 (Gibco) with 2.5% charcoal-stripped
(androgen-free) FBS (Gibco) in 96-well plates and incubated in 37°C (5 ×
103 cells/well, 6 wells/concentration and time point). After 24 hours, the
cells were incubated with indicated concentrations of DHT, T, or vehicle
for 7 days, and the absorbance was measured as described above.
Reinjection of Reestablished G Cells in Rat Prostate, Bone, and
Lungs
The reestablished cells were cultured for 5 to 8 passages (to reduce
stromal contamination), and then 2 × 105 cells from each cell line(G-original, G-bone-8w, G-bone-8w-cast, G-bone-12w, and
G-bone-12w-cast) were reinjected into the ventral prostate of new
recipient rats that had been castrated or sham treated 1 week earlier as
described above (n = 5 to 6 in each group). After six weeks, the
animals were sacrificed, and the tumors were removed, weighed, and
formalin fixed. The G-bone-12w tumor cells were also reinjected into
the bone marrow and prostate (2 × 105 cells/site, n = 7), and tumors
were formalin fixed after 4 weeks. Original G tumor cells and the
different sublines of G tumor cells reestablished from bone (7.5 × 105
cells in 0.3 ml of RPMI, n = 5 to 7 animals/cell type) were also
injected into the rat tail vein, and 10 weeks later, the lungs were
removed, weighed, and formalin fixed.
Statistical Analysis
Mann-Whitney U test and Kruskal-Wallis H test (both nonpara-
metric) were used for comparisons between groups. Any P value b .05
was considered significant. Statistical analysis was performed using
the statistical software SPSS version 22.0. Values presented are
mean ± SE.
Results
Establishment of G Tumors in Bone and Prostate
To examine the establishment and growth of prostate tumor in the
bone, we implanted androgen-sensitive G rat prostate tumor cells (2 ×
105 cells) into the tibial bone marrow of fully immune-competent
Copenhagen rats. At 8 weeks, small tumor foci (resembling
micrometastases) were found in the bone marrow (Figure 1A). At
12 weeks, the tumors were 3 times larger than at 8 weeks and
occupied substantial parts of the bone marrow cavity (macrometas-
tases), and they had sometimes grown outside the bone or into the
knee joint (Figure 1, A and B).
In addition, we implanted an equal number of G tumor cells in the
prostate to determine whether tumor establishment in the prostate
(i.e., the primary site) was different from that in the bone
microenvironment (i.e., the metastatic site). In the prostate, each
rat developed a single spherical tumor which, by 8 weeks, had
invaded the whole prostate (Figure 1A). At 12 weeks, the tumors
were twice as large as they had been 4 weeks earlier (Figure 1B). The
tumors established in the prostate were, however, 31 times larger at
8 weeks and 23 times larger at 12 weeks than the tumors established
in bone (Figure 1B), suggesting that, at least initially, the bone
microenvironment was of poorer quality for the tumor cells than the
prostate microenvironment.
Establishment of G Tumors in the Bone Microenvironment of
Castrated Rats
G tumors are not dependent on androgen for their survival, but
their growth rate is reduced when they grow subcutaneously in
castrated rats and mice [20,21].
To study how low androgen levels affected G tumor establishment
in the bone microenvironment, we implanted G tumor cells into the
tibial bone marrow of rats that had been castrated or sham operated 1
week earlier. As tumor establishment was slow in bone, we injected 10
times the number of cells described above (2 × 106) and evaluated
tumor size after 6 weeks. At this time point, there was no significant
difference between G tumors in the bone of control rats and castrated
rats (Figure 2A), indicating that androgen deprivation did not affect
tumor establishment in bone.
Figure 1. Establishment of G tumors in the bone versus the prostate microenvironment. G tumor cells (2 × 105) were implanted into the
tibial bone marrow or ventral prostate of fully immune-competent rats. (A) Representative sections, in low and high magnifications, of G
tumors in prostate at 8 weeks (encircled in black) and in bone at 8 weeks (encircled in black and with arrowheads) and 12 weeks
(encircled in black). High-resolution versions of G tumors in prostate and bone slides for use with the Virtual Microscope are available as
eSlide: VM02511 and as eSlide: VM02512. (B) Tumor area (mm2) in bone and prostate at 8 and 12 weeks. Values are mean ± SE; n = 6
to 10 animals in each group. *P b .05, **P b .01, ***P b .001.
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castrated or sham-operated rats, and tumor size was evaluated 6 weeks
later. Again, the tumors in control rats were significantly larger in the
prostate than in bone (Figure 2A). G tumor size in the prostate was,
however, significantly reduced (by 95%) in castrated rats, whereas no such
reduction was seen in the bone. Tumor proliferation (BrdU-labeling
index) was similar in control tumors in bone and prostate, showing that
tumor growth was similar at the end of the experiment. This suggests thattumor growth was comparable in the prostate and bone once the tumors
were established. At 6 weeks, proliferation was significantly reduced at
both sites in castrated compared with control rats (Figure 2B).
Castration Treatment of Established G Tumors in the Bone
Microenvironment
In the clinical setting, androgen deprivation is initiated when
patients already have advanced local or metastatic PC. We therefore
Figure 2. Tumor establishment in bone and prostate of castrated
and control rats. G tumor cells (2 × 106) were implanted into the
tibial bone marrow or prostate tissue of control or castrated rats,
and tumor size (A) and tumor proliferation (BrdU) (B) were analyzed
at 6 weeks. Values are mean ± SE, n = 8 to 12 animals in each
group, **P b .01, ***P b .001, ns = not significant.
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responded to castration. G tumor cells were implanted into the
prostate and bone marrow of the same animals. To somewhat
compensate for the slower tumor establishment in bone, we injected
100-fold more cells in the bone marrow (2 × 105) than in the prostate
(2 × 103). After 8 weeks, the animals were randomized to receive
either castration or control treatment, and the tumors were analyzed
14 days later. G tumors in the prostate of castrated rats were 83%
smaller than prostate tumors in control animals, whereas G tumor size
in bone was apparently unaffected by castration (Figure 3A).
Proliferation and apoptosis were unaffected by castration in the
tumors in bone (Figure 3, B and C). In contrast, proliferation was
significantly decreased and apoptosis significantly increased by
castration in the tumors in prostate (Figure 3, B and C). This
shows that the response to castration is reduced for G tumors growing
in bone compared with G tumors established in the prostate.
G Tumor Progression in the Bone Microenvironment
To further determine whether G tumor cells progress and change
their phenotype over time in the bone microenvironment, i.e.,
whether they gradually become more aggressive and/or castrationFigure 3. Castration treatment of established G tumors in the bone
marrow (2 × 105) and into the prostate tissue (2 × 103) and grown for
Tumor size (A), tumor proliferation (BrdU) (B), and tumor apoptosis (c
n = 7 to 8 animals in each group. *P b .05, **P b .01.resistant, G cells were again implanted into the tibial bone marrow of
rats that had been castrated or sham operated 1 week earlier
(Figure 4A). After tumor establishment, the G tumors were removed,
pooled, and reestablished as the following cell lines in vitro
(Figure 4A): 1) G cells from microscopic 8-week bone tumors of
control animals (G-bone-8w), 2) G cells from 8-week bone tumors of
castrated rats (G-bone-8w-cast), 3) G cells from macroscopic 12-week
bone tumors of control animals (G-bone-12w), and 4) G cells from
12-week bone tumors of castrated rats (G-bone-12w-cast).
No apparent difference was seen in the cell morphology between
the reestablished cell lines in vitro, and they were morphologically
similar to that of the original G cells (Figure 4B). The reestablished
tumor cells were cultured in vitro for several passages to reduce
possible contamination by stromal cells. In the bone-derived cell lines,
the gene expressions of mesenchymal markers and epithelial cell
markers did not indicate an enrichment of mesenchymal cells
compared with the original G cell line (unpublished observations
from whole genome expression array). G-bone-12w cells and
G-bone-12w-cast cells had higher viability in vitro than the
G-original, G-bone-8w, and G-bone-8w-cast tumors cells
(Figure 4C), indicating that G tumor cells from macroscopic bone
tumors had become more aggressive. Using Western blot, we
observed that all the different G cell lines expressed the AR with
slightly lower levels in G-bone-8w-cast cells and G-bone-12w-cast
cells (Figure 4D). A single band of the AR suggested that there were
no AR variants present (Figure 4D). In addition, nuclear AR levels
were also equal in the different cell types, suggesting that all the cell
lines still had the same amount of AR signaling (data not shown).
To compare the growth rates and androgen sensitivities of the
different bone-derived G tumor cell lines in vivo, we reinjected an equal
number of cells from each cell line into the prostate of new recipient rats
that had been castrated and control treated 1 week earlier, and then
analyzed the tumors 6 weeks later (Figure 5, A and C). G-bone-8w and
G-bone-8w-cast tumor cells gave slightly larger tumors than the
G-original cells when reinjected into the prostate, and both cell types
responded to castration with reduced tumor size compared with
controls (Figure 5A), suggesting that early and microscopic G prostate
tumors in bone had only somewhat progressed. Interestingly,
G-bone-12w and G-bone-12w-cast tumor cells were highly aggressive
when reinjected into the prostate (Figure 5A). G-bone-12w tumor cellsmicroenvironment. G tumor cells were implanted into the bone
8 weeks, and then the rats were either castrated or control treated.
aspase-3) (C) were analyzed 14 days later. Values are mean ± SE;
Figure 4. G tumor progression in the bone microenvironment. (A) G tumor cells (2 × 105) were injected into the tibial bone marrow of
castrated or control-treated rats and left for 8 or 12 weeks before tumors (n = 5 to 6 in each group) were removed, pooled, and
reestablished in vitro as the following cell lines: G cells from 8-week bone tumors of control animals (G-bone-8w), G cells from 8-week
bone tumors of castrated rats (G-bone-8w-cast), G cells from 12-week bone tumors of control animals (G-bone-12w), and G cells from
12-week bone tumors of castrated rats (G-bone-12w-cast). (B) Tumor cell morphology in vitrowas similar to that of the original G cells. (C)
Tumor cell viability measured for 7 days in vitro using anMTT assay, presented as fold change in mean absorbance (abs) ± SE compared
with day 1. **P b .01 compared with the original G cell line at day 7. (D) Western blot analyses showing androgen receptor levels in the
different G tumor cell lines.
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G tumors, and although the G-bone-12w tumors still responded to
castration, the magnitude of the response was less (tumor size in
castrated tumors was 62% of that in the controls) than in the original
tumors (11%of controls), the G-bone-8w tumors (8% of controls), and
the G-bone-8w-cast tumors (24% of controls) (Figure 5A). Reinjection
of G-bone-12w-cast tumor cells into the prostate resulted in the largest
tumors (28 times larger than the original G tumors), which were also
totally castration resistant (Figure 5A). In addition, the G-bone-12-
w-cast tumors differed in morphology from the other tumor types, with
large abnormal blood vessels with viable tumor tissue immediately
around each vessel, whereas areas further away from the vessels were
necrotic (Figure 5C). This suggests that, with time, the G tumors in the
bone microenvironment progress to an aggressive phenotype. Interest-
ingly, the G-bone-12w tumor cells had reduced androgen sensitivity in
vivo,which would suggest that the bone microenvironment per se could
promote castration resistance.
Next, we examined establishment of the aggressive G tumor cells in
bone. G-bone-12w tumor cells (2 × 105) were injected into both thetibial bone marrow and the prostate, and tumor size was evaluated
after 4 weeks. As early as 4 weeks, the G-bone-12w tumors were
established in the bone in 7 out of 7 animals, with a similar mean
tumor area (3.58 ± 1.79 mm2, n = 7) to that of the original G
tumors at 8 weeks (Figure 1B), suggesting that the tumor cells had
adapted to grow in the bone microenvironment. However, the
G-bone-12w tumor cells were still significantly smaller in the bone
than in the prostate (mean tumor area 29.85 ± 4.31 mm2,
n = 7;+P = .002), indicating that the bone microenvironment also
suppressed the growth of more aggressive tumors.
None of the G tumor cell lines that were reinjected into the prostate
were spontaneously metastasizing (data not shown). To examine tumor
colonization and growth in the lungs, the different G bone tumor cells
from bone were injected into the tail vein of rats. Both the G-bone-12w
tumors and the G-bone-12w-cast tumors had taken over most of the
lung tissue by 10 weeks, and the experiment had to be terminated
(Figure 5, B and D). At this time point, we could only find small
tumors in the lungs of animals injected with the G-original, the
G-bone-8w, and the G-bone-8w-cast tumor cells (Figure 5, B and D).
Figure 5. G tumor progression in the bone microenvironment. (A) Equal numbers (2 × 105 cells) from the different G tumor cell lines were
reinjected into the ventral prostate of recipient rats that had been castrated or control treated, and tumor weight was measured 6 weeks
later (values are mean ± SE, n = 6 to 8 in each group; *P b .05, **P b .01, ***P b .001). (B) Equal numbers of cells of each G cell line
(7.5 × 105) were injected into the tail vein, and tumor colonization in lungs was examined 10 weeks later (values are mean tumor weight in
lungs ± SE, n = 5 to 7 in each group, **P b .01 compared with G-original cells). (C) Sections of the different G tumors in prostate. Note
the changed morphology in the G-bone-cast-12w tumors, with viable tumor tissue growing around large blood vessels. High-resolution
versions of G-bone-8w-cast and G-bone-12w-cast slides for use with the Virtual Microscope are available as eSlide: VM02513 and as
eSlide: VM02514. (D) Representative sections, in low and high magnifications, showing lung tumor burden for the different cell lines.
High-resolution versions of G-bone-8w and G-bone-12w slides for use with the Virtual Microscope are available as eSlide: VM02515 and
as eSlide: VM02516.
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either G-bone-12w cells or G-bone-12w-cast cells compared with the
other three cell types (Figure 5B). Our results show that G tumor cells
that had progressed in the bone microenvironment had an increased
capacity to colonize secondary organs, such as the lungs. Tumor cells
growing in bone could therefore be a source of a subsequent (i.e.,
secondary) wave of metastatic dissemination to other tissues or back to
the prostate [14,15].
Taken together, the difference between tumor cells from
microscopic 8-week and macroscopic 12-week G prostate bone
tumors showed that new tumor cell characteristics, resulting in moreaggressive tumor cells with reduced androgen sensitivity, were stably
acquired with time in the bone microenvironment.
Concentrations of Testosterone and Dihydrotestosterone in the
Normal Prostate and Bone
Slow initial growth and the subsequent development of an
aggressive tumor cell phenotype in the bone could be due to
microenvironmental factors. Using liquid chromatography–tandem
mass spectrometry [18], we therefore compared the local levels of T
and DHT in prostate tissue and bone marrow of tumor-free control
rats and tumor-free castrated rats. In the prostate tissue, the
Figure 6. G tumor cell viability in response to androgens. G tumor
cell viability in vitro was measured 0, 4, and 7 days after incubation
with DHT or T at different concentrations using an MTT assay.
Values are mean absorbance ± SE.
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previous reports [22]. Although T signals were detected in prostate
tissue of untreated rats, the levels were below the quantification limit
(Table 1). This indicates that T is rapidly converted to DHT in the
prostate. The bone marrow did not contain measurable DHT, and
the concentration of T was six times lower than the intraprostatic
levels of DHT (Table 1). In castrated rats, the amount of T was below
the limit of detection in both prostate and bone marrow, and the
amount of DHT was highly reduced or absent in the prostate
(Table 1). T and DHT were also measured in plasma, and the
concentrations were similar to those previously reported for male rats
[22] (Table 1). This shows a difference in both the type and the levels
of androgens in prostate tissue and bone marrow.
To study how androgens directly affect G tumor growth and if
there was a difference between T and DHT, the cells were stimulated
with different concentrations of DHT and T in vitro, and tumor cell
viability was measured using an MTT assay. The G tumor cells were
able to survive for 7 days without any androgens but ceased growing
(Figure 6). Both DHT and T were equally effective in stimulating the
growth of G tumor cell in vitro (Figure 6). This suggests that
differences in tumor establishment in bone and prostate in vivo are
probably not due to variations in the types of androgens.
Furthermore, both types of androgens affected tumor cell growth in
a dose-dependent manner (Figure 6). The higher levels of androgens
in prostate tissue in vivo than in the levels in bone marrow may
therefore, hypothetically, enhance tumor cell growth in the prostate
relative to tumor cell growth in bone.
Hypoxic Conditions inGTumors in the BoneMarrow andProstate
Recent studies have shown that bone marrow is highly hypoxic
under normal conditions [23]. Hypoxia is known to both suppress
tumor growth and drive tumor progression [24]. Using oxygen
electrodes and hypoxyprobe staining, we therefore examined the
extent of tissue hypoxia in the prostate and bone marrow at the time
of tumor cell injection in both castrated rats and control rats.
Hypoxyprobe staining of the tibial bone marrow of untreated rats
showed intense staining along the surface of the bone and in scattered
islands of hematopoietic cells in the interior of the bone marrow
cavity (Figure 7). It was also possible to find areas without staining.
The mean oxygen tension (pO2) was 12.2 ± 1.8 mm Hg (n = 18) in
the tibial bone marrow cavity. Seven days after castration, the bone
marrow still had intense hypoxyprobe staining, indicating a strong
degree of hypoxia (Figure 7), and the mean pO2 was 8.3 ± 1.2 mm
Hg (n = 19). Our previous studies show that castration rapidly reduce
prostate blood flow [25] and this results in hypoxia [26,27]. Oxygen
levels return to normal levels by day 7 possibly because of low
consumption in atrophic glands [26]. In line with this, most of the
atrophic prostate glands were unstained at day 7 after castration (dataTable 1. Androgen Concentrations in Prostate and Bone Marrow of Tumor-Free Rats
Testosterone (T)
(pmol/g Tissue)
(pmol/ml Plasma)
Dihydrotestosterone (DHT)
(pmol/g Tissue)
(pmol/ml Plasma)
Control Castrated Control Castrated
Prostate b0.12* 0 17.8 ± 3.6 0.06 ± 0.09
Bone marrow 2.9 ± 1.3 0 0 0
Plasma 5.9 ± 2.4 0 1.0 ± 0.9 0
Values are mean ± SD, n = 7 in each group,
*Corresponds to the lowest concentration on the calibration curve.not shown) and as described earlier [26,27]. The mean pO2 in control
prostates (27.2 ± 1.3 mm Hg, n = 13) was significantly higher than
in the bone marrow (P b .001). We were, however, unable to
measure pO2 in the small prostate remaining at day 7 after castration.Figure 7. Hypoxia in the bone marrow and prostate. Sections from
bone tissue in controls and 7 days after castration, stained for
hypoxia (Hypoxyprobe, brown), in low and high magnifications. A
high-resolution version of this slide for use with the Virtual
Microscope is available as eSlide: VM02517.
160 Prostate tumor progression in bone Bergström et al. Neoplasia Vol. 18, No. 3, 2016Taken together, these results show that G tumor cells implanted in
bone need to adapt to a more hypoxic environment than that in the
prostate, and this might possibly contribute to the reduced initial
tumor growth but also to a stronger selective pressure at the bone
metastatic site.
Discussion
To understand the metastatic progression within the bone microenvi-
ronment is probably the key to improve treatments for PC metastases.
Here we developed an androgen-sensitive rat prostate tumor model and
simulated metastases in the bone of fully immune-competent rats. This is
an advantage to many other metastasis models that use already
castration-resistant tumor cells in immune-compromised animals. We
show that G tumor cells reestablished from overt metastases in bone
(12 weeks) of both castrated rats and control rats were highly aggressive,
with increased ability to grow in prostate, bone, and lungs, in comparison
toG tumor cells reestablished from small tumors in bone (8 weeks) and in
comparison to the original G tumor cells. Along with this, PC bone
metastases in patients seed new metastasis and also reseed back to the
prostate [14,15]. Interestingly, dormant breast cancer cells from the bone
marrow were highly aggressive when injected at the primary site [28],
suggesting that the more aggressive phenotype induced within the bone
may show its full potential when the cells arrive at a new site. It appears
that slow-growing PC cells within the bone may, with time, acquire traits
that facilitate their growth if they reseed the prostate or spread to other
secondary sites. This hypothesis is line with the parallel progressionmodel
[3], suggesting that early disseminated tumor cells surviving at secondary
sites progress differently than those remaining in the primary tumor. Our
experimental model can be used to explore the microenvironmental
factors in the bone that could be important for metastatic progression and
secondary PC metastatic spread.
Furthermore, G tumor cells reestablished from 12-week bone
metastases of control rats had reduced androgen sensitivity in the prostate
compared with the original G cells, suggesting that the bone
microenvironment per se promotes castration resistance. Not surprisingly,
tumor cells from 12-week bone metastases in castrated rats were totally
castration resistant.However, G tumor cells from8-week bonemetastases
in both control rats and castrated rats were still androgen sensitive,
suggesting that environment-induced castration resistance may need
some time to develop. PCs progress in response to androgen deprivation
[29], and mutations promoting castration resistance seem to occur after
metastatic spread [14]. The mechanisms behind bone-induced versus
treatment-induced castration resistance and progression in our model are,
at present, unknown. However, up to five serial passages of subcutaneous
G tumors in castrated rats did not cause progression of the tumor cells
[30], suggesting that the bone microenvironment specifically accelerates
prostate tumor progression. We are currently exploring gene expression
and genetic and epigenetic profiles of the different G tumor cells from
bone to reveal possible novel mechanisms or if mechanisms for castration
resistance already shown to be of importance in patients [31] are involved.
The possibility that a few cells from the bone microenvironment, such as
mesenchymal stem cells [32], may actually survive in the reestablished cell
lines and be of functional importance when the cells are injected back into
the prostate is also investigated.
Castration treatment before the arrival of tumor cells did not affect
G tumor establishment in bone, perhaps suggesting that early
androgen deprivation may not affect metastatic colonization in bone.
Furthermore, established G tumors in bone did not respond to
castration treatment, whereas castration markedly reduced growth ofestablished tumors in the prostate. In line with this, treatment with
the antiandrogen bicalutamide reduced tumor growth of a PC
xenograft transplanted subcutaneously but not when the same tumor
was transplanted into the bone [33]. It appears that the response to
castration treatment could be microenvironment dependent. If so,
this is of considerable clinical importance.
In this study, we started to explore potential factors in the bone
microenvironment that could be involved in the reduced response to
castration, the slow initial growth, and the selection of aggressive
cancer cells. Here we show that androgen levels are lower in bone than
in prostate and that the bone marrow is hypoxic. Whether local
androgen levels affect metastatic establishment and progression is
unknown and warrants further studies. Hypoxia may induce
dormancy in PC metastases [34], suggesting that hypoxia may
initiate a more quiescent tumor cell phenotype. Hypoxia may also
select for more androgen-independent prostate tumor cells and
promote an aggressive tumor cell phenotype [24,35–37]. The
reduced response to castration in bone could be due to lack of
factors needed for a full castration response. Castration-induced
inhibition of primary prostate tumor growth is the result of several
factors acting together: direct effects of androgen shortage in epithelial
cells, reduced trophic influence from the androgen-dependent
prostate stroma, and reduced prostate blood flow causing hypoxia-
induced epithelial cell death [17,38–40]. The bone marrow is highly
hypoxic already under normal conditions [23], and hypoxia did not
appear to increase by castration. Increased hypoxia-induced cell
death, as a result of castration, is therefore not likely in the bone
environment, and it is unclear whether the bone metastasis stroma
and vasculature are as androgen dependent as those in the prostate
[41].
In conclusion, using this rat prostate tumor model, we have shown
that tumor cells growing in the bone marrow experience lower
androgen levels and a higher degree of hypoxia compared with those
in the prostate. Importantly, the tumor cells that do survive in the
inhospitable microenvironment of bone adapt with time and become
much more aggressive and castration resistant. Further studies are
therefore needed to detect and treat metastases early before they have
progressed and to find mechanisms contributing to the metastatic
progression. This tumor model represents different stages of
metastatic disease, and it can be used to study processes and
mechanisms that are important in metastatic growth and progression
to find novel therapeutic targets for bone metastases.
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